RecruitingPhase 3NCT02670707
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Studying Langerhans cell histiocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Baylor College of Medicine
- Principal Investigator
- Olive Eckstein, MDBaylor College of Medicine
- Intervention
- Cytarabine(drug)
- Enrollment
- 124 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2016 – 2029
Study locations (11)
- Stanford Children's Hospital, Lucile Packard Children's Hospital, Palo Alto, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Lehigh Valley Health Network- Cedar Crest, Allentown, Pennsylvania, United States
- Dell Children's Medical Center, Austin, Texas, United States
- Cook Children's Health Care System, Fort Worth, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
- Vannie Cook Children's Clinic, McAllen, Texas, United States
- Children's Hospital of San Antonio, San Antonio, Texas, United States
- Children's Hospital of The King's Daughters, Norfolk, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02670707 on ClinicalTrials.govOther trials for Langerhans cell histiocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07371182Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone LesionsWest China Second University Hospital
- RECRUITINGNANCT07431060Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell HistiocytosisWest China Second University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT07204041Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPHASE2NCT07022834Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in ChildrenWest China Second University Hospital
- RECRUITINGPHASE2NCT07187193Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCHCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ENROLLING BY INVITATIONPHASE1NCT06902792Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsSecond Affiliated Hospital of Wenzhou Medical University
- RECRUITINGPHASE2NCT06582745Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibCook Children's Health Care System
- RECRUITINGPHASE2NCT05828069A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisNational Cancer Institute (NCI)